D-2570 treatment for people with active psoriatic arthritis (Phase II)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, placebo-controlled multicenter Phase II trial enrolling about 222 adults with active psoriatic arthritis. Participants are randomized into three equal groups (74 per group) that differ by D-2570 dose or placebo, with identical eligibility, blinding, and outcome assessments across groups. The study measures both safety and efficacy outcomes to see if D-2570 improves joint signs and symptoms while monitoring adverse events. Standard clinical joint counts and other relevant disease activity measures will be used to compare D-2570 against placebo over the treatment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;
2. Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;
3. Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;
4. Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).

Exclusion Criteria:

1. History of infection as defined in the protocol;
2. Any of the medical diseases or disorders listed in the protocol;
3. Significant, uncontrolled or unstable disease in any organ.

Where it's running

• West China School of Medicine
  Chengdu, Sichuan, China Recruiting

Study contacts

• Principal investigator: yi liu, phD — West China School of Medicine
• Study coordinator: yi liu, Dr.
• Email: zhongchen.ma@inventisbio.com
• Phone: 13401466347

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing D-2570 in adults with varying kidney function

  This study tests a single dose of D-2570 in adults aged 18–70 with different levels of kidney function to see how the drug behaves in the body.

  Recruiting Phase 1 InventisBio Co., Ltd · Hefei, Anhui · NCT07715175

• Pharmacokinetics of D-2570 in people with liver impairment and in healthy volunteers

  This study tests how D-2570 moves through and affects the body in adults with liver impairment compared to those with normal liver function.

  Recruiting Phase 1 InventisBio Co., Ltd · Bengbu, Anhui · NCT07715149

• D-2570 in Non-Segmental Vitiligo (Phase 2)

  This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.

  Recruiting Phase 2 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07625891

• D-2570 in Moderate to Severe Plaque Psoriasis

  This study tests whether D-2570 can safely improve symptoms in adults with moderate to severe plaque psoriasis.

  Recruiting at 3 sites Phase 2 InventisBio Co., Ltd · Birmingham, Alabama and 19 other locations · NCT07489885

• D-2570 oral treatment for adults with moderate to severe plaque psoriasis

  This trial tests whether the oral medicine D-2570 helps adults with moderate to severe plaque psoriasis compared with placebo and an approved oral drug.

  Recruiting Phase 3 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07326813

• D-2570 treatment for active systemic lupus erythematosus

  This trial will test whether daily D-2570 helps adults (18–70) with active systemic lupus erythematosus control their symptoms and disease activity better than a placebo over 48 weeks.

  Recruiting Phase 2 InventisBio Co., Ltd · Linfen, Jiangxi · NCT07311200

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.